Insights from Global Analyses of Long Noncoding RNAs in Breast Cancer

Warburton AJ, Boone DN. Insights of Global Analyses of Long Noncoding RNAs in Breast Cancer. Curr Pathobiol Rep. 2017 Mar;5(1):23-34. doi: 10.1007/s40139-017-0122-1. Epub 2017 Jan 23. PubMed PMID: 28616363. PubMed Central PMCID: PMC5467540.

PURPOSE OF REVIEW:

The goal of this review was to compare and contrast the results and implications from several recent transcriptomic studies that analyzed the expression of lncRNAs in breast cancer. How many lncRNAs are dysregulated in breast cancer? Do dysregulated lncRNAs contribute to breast cancer etiology? Are lncRNAs viable biomarkers in breast cancer?

RECENT FINDINGS:

Transcriptomic profiling of breast cancer tissues, mostly from The Cancer Genome Atlas, identified thousands of long noncoding RNAs that are expressed and dysregulated in breast cancer. The expression of lncRNAs alone can divide patients into molecular subtypes. Subsequent functional studies demonstrated that several of these lncRNAs have important roles in breast cancer cell biology.

SUMMARY:

Thousands of lncRNAs are dysregulated in breast cancer that can be developed as biomarkers for prognostic or therapeutic purposes. The reviewed reports provide a roadmap to guide functional studies to discover lncRNAs with critical biological functions relating to breast cancer development and progression.

Publication Year: 
2017
Faculty Author: 
Publication Credits: 
Warburton AJ, Boone DN
AttachmentSize
PDF icon InsightsfromGlobalAnalyses.pdf419.29 KB
^